Biosimilar PBS Listing: Cipla’s Adalicip® Biosimilar to AbbVie’s Humira® PBS-Listed

Cipla’s Adalicip®, developed by Alvotech (AVT02), biosimilar to AbbVie’s Humira® (adalimumab) has been listed on the PBS (General Pharmaceutical Benefits) in the 40mg/0.4mL dosage in syringes and pen devices.  It is reimbursed to treat various conditions, including Crohn’s disease, ulcerative colitis and rheumatoid arthritis.

Cipla’s public summary document for Adalicip® was published on 27 October 2023, and it was considered at the July 2023 PBAC meeting.